60 results about "NERVOUS DISORDERS" patented technology

The invention relates to the technical field of medical informatics, in particular to an ADL ability training data management system based on neurological disease patients. The system comprises a memory and a processor, and the processor executes computer programs stored in the memory so as to realize the following steps: acquiring attitude images and scales of normal personnel and neurological disease patients in the ADL ability training process; according to the position difference, the depth difference and the time difference between the joint points in the to-be-evaluated image and the joint points in the reference image, evaluating the possibility value that the to-be-evaluated image and the reference image are in the same action, and screening a contrast image; synthesizing the possibility value that the to-be-evaluated image and all the contrast images are in the same action and the acquisition time of the to-be-evaluated image to obtain a motion completion index; and determining an effective evaluation value of training according to the difference between the change characteristics of each type of indexes of the neurological disease patient at each moment and other indexes and each type of indexes. According to the invention, an accurate comprehensive result of ADL capability training data can be obtained.

The invention discloses a neural disease diagnosis system based on space-time attention and dynamic field self-adaption. The method belongs to the technical field of cross-modal medical data adaptive analysis. The technical problem that a brand new system capable of simultaneously fusing multi-modal information and modeling multi-scale spatial-temporal features and having dynamic field adaptive ability is urgently needed to improve the accuracy and generalization ability of intelligent diagnosis of multi-site nerve diseases is solved. The system comprises a data preprocessing module for extracting a standardized time sequence of a brain region from fMRI time sequence data; the two-channel feature coding network module obtains global features through an attention mechanism; according to the feature fusion and classification module, a main task classifier executes a main task and predicts whether a to-be-tested person suffers from nerve diseases or not, and a domain task classifier executes a domain task and predicts a site to which the to-be-tested person belongs; and the dynamic balance training module adjusts the dynamic balance of the main task and the domain task through a dynamic balance control strategy.

A method comprising to analyze the captured video data of the patient's body parts and to generate patient motion metrics, patient posture metrics, and patient gait metrics for each exercise routine completed by the patient based on the analyzed video data; store, in a database, the generated patient motion metrics, the patient posture metrics and the patient gait metrics for each of the completed exercise routines, wherein the generated patient motion metrics, the generated patient posture metrics and the generated patient gait metrics are used to track patient progress during physical therapy sessions, diagnose movement disorders, and provide personalized, data-driven treatment plans to enhance immediate outcomes and long-term recovery with respect to the musculoskeletal and neurological disorders; apply motion amplification algorithms to enhance the additional video data to provide clarity of tremor movements; apply edge detection to enhance tremor movement boundaries and detection; generate tremor amplitude measurements and tremor frequency measurements based on the motion amplification and edge detection algorithms; and store, in the database, the generated tremor amplitude measurements and tremor frequency measurements, wherein the generated tremor amplitude measurements and tremor frequency measurements are analyzed for diagnosis and monitoring of disorders such as Parkinson's disease and Essential Tremor.

The present application relates to the technical field of postoperative rehabilitation, in particular to a postoperative rehabilitation intervention system for patients with neurological diseases based on evidence-based medical evidence. The steps implemented by the system include: obtaining characteristic data of a patient with a neurological disease to be analyzed and reference patients, a rehabilitation scheme of the reference patients and a postoperative Barthel index, calculating a reference factor of the reference patients corresponding to each rehabilitation scheme under each preoperative state; obtaining a comprehensive Barthel index of each rehabilitation scheme under each preoperative state by using the reference factor and the postoperative Barthel index, determining a correction factor under each preoperative state according to the comprehensive Barthel index, and correcting the comprehensive Barthel index to obtain a target Barthel index; determining a reference rehabilitation scheme by combining the similarity of the characteristic data of the patient with a neurological disease to be analyzed and different reference patients and the target Barthel index. The present application can improve the postoperative rehabilitation intervention effect for patients with neurological diseases.

The present disclosure relates to the method of treating neurological disease in a recreational drug user by administering an effective amount of soticlestat or a pharmaceutically acceptable salt thereof, wherein the treatment does not produce the potential of drug abuse.

The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg / ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

To provide a drug having positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.SOLUTION: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons.SELECTED DRAWING: Figure 12

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

The present invention relates to nitrogen-containing heterocyclic compound derivatives and uses thereof. The compounds according to the present invention can exert therapeutic effects on various neurological disorders, such as neurodegenerative diseases, neurodegenerative pathologies, neuropsychiatric disorders, memory loss, cognitive dysfunction / impairment, and impairment of extinction learning, by effectively enhancing synaptic plasticity without side effects.

The invention discloses a brain venation plexus vesicle segmentation method, and the method comprises the steps: firstly reinforcing the signal contrast of the whole venation plexus through a high-resolution T1 enhanced image, and then achieving the stable segmentation of vesicles through employing the two steps: the whole segmentation of the venation plexus and the segmentation of the vesicles. In the vesicle segmentation process, as the vesicles are filled with cerebrospinal fluid, the difference between a venation plexus entity (high signal) and the cerebrospinal fluid (low signal) in a T1 enhanced image is utilized, a vesicle segmentation reference threshold value is set, and vesicle voxel separation is realized through low-pass filtering. According to the method, the vesicle structure of the cerebral venation plexus can be segmented, the volume of the vesicle structure can be calculated, and the volume of the vesicle of the cerebral venation plexus can be used as an image marker for auxiliary diagnosis of nerve diseases such as Alzheimer's disease.

A compound represented by formula (I) or a tautomer, optical isomer, deuterated substance, oxynitride, solvate, pharmaceutically acceptable salt or prodrug thereof can be used in preparing a pharmaceutical composition. The compound or the pharmaceutical composition can be used in the preparation a drug for the prevention and / or treatment of cancer, tumors, viral infections, depression, neurological disorders, trauma, age-related cataracts, organ transplant rejection or autoimmune diseases.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with phenoxy or benzyloxy substituted psychoplastogens.

This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of or improving a pathology of a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder, or for enhancing neuroplasticity in a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder making use of the combinations, compositions and kits of this invention.

The present application discloses a gait analysis method, device, system, electronic device and storage medium. The gait analysis method includes: simultaneously acquiring the bioelectrical signals of a target object and dual-view synchronized videos during the movement of the target object; extracting gait parameters from the dual-view synchronized videos through a lightweight pose estimation network model; performing feature extraction on the bioelectrical signals to obtain bioelectrical signal feature parameters; and combining the gait parameters and the bioelectrical signal feature parameters to obtain a comprehensive gait analysis result. The gait analysis method provided by the embodiments of the present application acquires relatively comprehensive data, improves the calculation rate and reduces the analysis cost through a lightweight algorithm, and the gait analysis result obtained by combining bioelectrical signals and dual-view synchronized videos is relatively accurate, which can meet the requirements for the comprehensiveness of various types of data in current neurological disease research, realize the quantitative evaluation of neurological diseases, and promote the research progress of neurological diseases.

The invention relates to the technical field of data management, in particular to a neurology patient data management method and system, and the method comprises the following steps: carrying out the multi-source data collection of a neurology patient; performing data standardization preprocessing operation; the method comprises the following steps: performing preliminary division on neural disease subtypes by adopting fuzzy clustering and fuzzy logic rules, defining fuzzy boundaries among the subtypes, and outputting fuzzy feature data comprising subtype fuzzy membership degrees and related overlapping features; and performing stable identification on the subtype fuzzy boundary of the neurological disease of the patient, and outputting an intelligent analysis result including each subtype fuzzy classification result, membership information and overlapping region description. According to the method, the problem of unstable classification caused by fuzzy boundary of a traditional neural disease classification method is effectively solved, the misjudgment rate of a classification model is reduced, meanwhile, the adaptability of the model to patients with transition among subtypes is enhanced, and the clinical reliability and interpretability of classification are improved.

Provided herein are methods and compositions for prevention of, reduction of risk of, amelioration of, and / or treatment of neurological disorders, particularly neurological disorders characterized by neurodegeneration and / or neuroinflammation. In particular aspects, methods and / or compositions include means for transgenically overexpressing NFIA, SOX9, A2M, and / or MEGF10 in one or more populations of cells, such as astrocytes.

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Disclosed herein are antibodies and / or antibody binding fragments having a leukocyte immunoglobulin-like receptor B (LILRB) binding domain. Also provided herein are methods of modulating the production and / or accumulation of amyloid-β (Aβ) in a subject. Further disclosed herein are recombinant antibodies and methods of using thereof. Additionally described herein are methods for treating and / or preventing a neurological disorder in a subject. The present disclosure further provides transgenic non-human animals having diminished amyloid-β (Aβ) pathology. Further provided are methods of identifying compounds or antibodies for treating and / or preventing a neurological disorder in a subject.

The present inventive concept provides a subject's fecal protein bioprofile and methods for establishing the same. Also provided are methods of determining a subject's risk for developing an inflammatory disorder, a neurological disorder, a neurodegenerative disorder, or a disorder associated with aging or monitoring the same. The inventive concept further provides kits for use in the methods described herein.

The present invention relates to a steroid compound, a use thereof and a preparation method therefor. It is expected that such compound can effectively treat mental and neurological diseases, and has good active efficacy, pharmacokinetic (PK) performance, oral bioavailability, stability, safety, clearance rate, and / or metabolic performance and the like.

Provided herein are methods for reducing reactive microglia in a subject. Further provided herein are methods for treating a neurological disease, disorder, or condition in a subject. In some cases, the methods involve administering a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor to the subject. In some cases, the 15-PGDH inhibitor can penetrate the blood-brain barrier.

Provided, in part, are compounds of Formula I.pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with the activity of sodium channels. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Photobiomodulation (PBM) can be delivered to small fibers within a target nerve before, during, and / or after surgery (using a surgical tool and a controller) to silence small fibers within the target nerve to treat one or more neurological disorders (e.g., nociceptive pain). By silencing small fibers conveying nociceptive information, acute nociceptive pain can be dulled and chronification of acute nociceptive pain can be slowed, halted, and / or prevented. The surgical tool includes an optical emitter, a body configured to hold the optical emitter, and a shield coupled to and / or incorporated into the body. The body can direct a dose of PBM to a target through a surgical opening. The shield can be positioned to extend outward from the body and to contain at least a portion of excess light of the dose of PBM. The controller can set the dose of PBM at an amount for a time.

The invention relates to the technical field of transcranial magnetic stimulation, in particular to a transcranial magnetic stimulation system and method controlled by electroencephalogram signals. The system comprises an electroencephalogram acquisition module, a self-adaptive signal processing module, a dynamic stimulation control module, a reconfigurable transcranial magnetic stimulation module and a closed-loop feedback regulation module. The method comprises the following steps: collecting and preprocessing electroencephalogram signals of a subject; extracting multi-dimensional electroencephalogram features by combining wavelet packet decomposition and Hilbert-Huang transform through denoising of an improved U-Net model fused with physiological priori; dynamically optimizing stimulation parameters based on a particle swarm optimization algorithm; magnetic field focusing is realized by using a flexible coil array, and synchronous stimulation pulses are output by combining a phase locking mechanism; closed-loop feedback adjustment ensures that the stimulation effect reaches the standard. The problems that a traditional system is low in electroencephalogram analysis precision, poor in parameter adaptability, insufficient in focusing and low in synchronization precision are solved, the nerve regulation and control effect is improved, the damage risk of a non-target brain region is reduced, and the method is suitable for personalized treatment of nerve diseases such as depression and dyskinesia after cerebral apoplexy.

The present invention provides novel transdermal delivery devices (or patches) comprising dextromethorphan, pharmaceutical compositions comprising dextromethorphan, methods of making the same, and methods of transdermal administration of dextromethorphan. Also provided herein are methods of treating a variety of diseases and disorders, such as neurological diseases or neurological disorders (e.g., PBA), using the transdermal delivery devices and / or pharmaceutical compositions herein.

The present application relates to the technical field of biological medicine, and particularly relates to the use of fisetin in preventing / treating KIF1A related neurological diseases. The inventor of the present application first discovers and confirms that treating Caenorhabditis elegans with R11Q mutation with plant flavonol fisetin can improve the movement of the animals. The discovery of the present application makes it possible to rescue R11Q deficiency at the biochemical and animal levels, and provides a new clue for the treatment of KIF1A related neurological diseases.

The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of polynucleotides encoding AADC. The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of AAV vectors which include polynucleotides encoding AADC. The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of polynucleotides encoding AADC in the treatment of neurological diseases, disorders and conditions, including Parkinson's Disease.